Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial
Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, ther...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Coats, Andrew J. Stewart [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet - Fabersani, Emanuel ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:176 ; year:2014 ; number:3 ; day:20 ; month:10 ; pages:600-604 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijcard.2014.05.034 |
|---|
| Katalog-ID: |
ELV012111546 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV012111546 | ||
| 003 | DE-627 | ||
| 005 | 20230625110407.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2014.05.034 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014006000001.pica |
| 035 | |a (DE-627)ELV012111546 | ||
| 035 | |a (ELSEVIER)S0167-5273(14)01017-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 630 |a 640 |a 610 |q VZ |
| 100 | 1 | |a Coats, Andrew J. Stewart |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. | ||
| 520 | |a Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. | ||
| 700 | 1 | |a Nijjer, Sukhjinder S. |4 oth | |
| 700 | 1 | |a Francis, Darrel P. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Fabersani, Emanuel ELSEVIER |t Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000849189 |
| 773 | 1 | 8 | |g volume:176 |g year:2014 |g number:3 |g day:20 |g month:10 |g pages:600-604 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijcard.2014.05.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 176 |j 2014 |e 3 |b 20 |c 1020 |h 600-604 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a j s c ajs ajsc |
|---|---|
| matchkey_str |
coatsandrewjstewartnijjersukhjindersfran:2014----:rtcighpplnosinepnescetfcehdadhlsosrm |
| hierarchy_sort_str |
2014transfer abstract |
| publishDate |
2014 |
| allfields |
10.1016/j.ijcard.2014.05.034 doi GBVA2014006000001.pica (DE-627)ELV012111546 (ELSEVIER)S0167-5273(14)01017-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Coats, Andrew J. Stewart verfasserin aut Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial 2014transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Nijjer, Sukhjinder S. oth Francis, Darrel P. oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 https://doi.org/10.1016/j.ijcard.2014.05.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 176 2014 3 20 1020 600-604 5 045F 610 |
| spelling |
10.1016/j.ijcard.2014.05.034 doi GBVA2014006000001.pica (DE-627)ELV012111546 (ELSEVIER)S0167-5273(14)01017-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Coats, Andrew J. Stewart verfasserin aut Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial 2014transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Nijjer, Sukhjinder S. oth Francis, Darrel P. oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 https://doi.org/10.1016/j.ijcard.2014.05.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 176 2014 3 20 1020 600-604 5 045F 610 |
| allfields_unstemmed |
10.1016/j.ijcard.2014.05.034 doi GBVA2014006000001.pica (DE-627)ELV012111546 (ELSEVIER)S0167-5273(14)01017-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Coats, Andrew J. Stewart verfasserin aut Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial 2014transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Nijjer, Sukhjinder S. oth Francis, Darrel P. oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 https://doi.org/10.1016/j.ijcard.2014.05.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 176 2014 3 20 1020 600-604 5 045F 610 |
| allfieldsGer |
10.1016/j.ijcard.2014.05.034 doi GBVA2014006000001.pica (DE-627)ELV012111546 (ELSEVIER)S0167-5273(14)01017-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Coats, Andrew J. Stewart verfasserin aut Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial 2014transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Nijjer, Sukhjinder S. oth Francis, Darrel P. oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 https://doi.org/10.1016/j.ijcard.2014.05.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 176 2014 3 20 1020 600-604 5 045F 610 |
| allfieldsSound |
10.1016/j.ijcard.2014.05.034 doi GBVA2014006000001.pica (DE-627)ELV012111546 (ELSEVIER)S0167-5273(14)01017-1 DE-627 ger DE-627 rakwb eng 610 610 DE-600 630 640 610 VZ Coats, Andrew J. Stewart verfasserin aut Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial 2014transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. Nijjer, Sukhjinder S. oth Francis, Darrel P. oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 https://doi.org/10.1016/j.ijcard.2014.05.034 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 176 2014 3 20 1020 600-604 5 045F 610 |
| language |
English |
| source |
Enthalten in Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet Amsterdam [u.a.] volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 |
| sourceStr |
Enthalten in Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet Amsterdam [u.a.] volume:176 year:2014 number:3 day:20 month:10 pages:600-604 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| authorswithroles_txt_mv |
Coats, Andrew J. Stewart @@aut@@ Nijjer, Sukhjinder S. @@oth@@ Francis, Darrel P. @@oth@@ |
| publishDateDaySort_date |
2014-01-20T00:00:00Z |
| hierarchy_top_id |
ELV000849189 |
| dewey-sort |
3610 |
| id |
ELV012111546 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV012111546</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625110407.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijcard.2014.05.034</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014006000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV012111546</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-5273(14)01017-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Coats, Andrew J. Stewart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nijjer, Sukhjinder S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Francis, Darrel P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Fabersani, Emanuel ELSEVIER</subfield><subfield code="t">Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000849189</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:176</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:3</subfield><subfield code="g">day:20</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:600-604</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijcard.2014.05.034</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">176</subfield><subfield code="j">2014</subfield><subfield code="e">3</subfield><subfield code="b">20</subfield><subfield code="c">1020</subfield><subfield code="h">600-604</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Coats, Andrew J. Stewart |
| spellingShingle |
Coats, Andrew J. Stewart ddc 610 ddc 630 Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| authorStr |
Coats, Andrew J. Stewart |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000849189 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 630 - Agriculture & related technologies 640 - Home & family management |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 630 640 610 VZ Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| topic |
ddc 610 ddc 630 |
| topic_unstemmed |
ddc 610 ddc 630 |
| topic_browse |
ddc 610 ddc 630 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s s n ss ssn d p f dp dpf |
| hierarchy_parent_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| hierarchy_parent_id |
ELV000849189 |
| dewey-tens |
610 - Medicine & health 630 - Agriculture 640 - Home & family management |
| hierarchy_top_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000849189 |
| title |
Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| ctrlnum |
(DE-627)ELV012111546 (ELSEVIER)S0167-5273(14)01017-1 |
| title_full |
Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| author_sort |
Coats, Andrew J. Stewart |
| journal |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| journalStr |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
600 |
| author_browse |
Coats, Andrew J. Stewart |
| container_volume |
176 |
| physical |
5 |
| class |
610 610 DE-600 630 640 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Coats, Andrew J. Stewart |
| doi_str_mv |
10.1016/j.ijcard.2014.05.034 |
| dewey-full |
610 630 640 |
| title_sort |
protecting the pipeline of science: openness, scientific methods and the lessons from ticagrelor and the plato trial |
| title_auth |
Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| abstract |
Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. |
| abstractGer |
Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. |
| abstract_unstemmed |
Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial |
| url |
https://doi.org/10.1016/j.ijcard.2014.05.034 |
| remote_bool |
true |
| author2 |
Nijjer, Sukhjinder S. Francis, Darrel P. |
| author2Str |
Nijjer, Sukhjinder S. Francis, Darrel P. |
| ppnlink |
ELV000849189 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ijcard.2014.05.034 |
| up_date |
2024-07-06T21:30:43.068Z |
| _version_ |
1803866805967519744 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV012111546</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625110407.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijcard.2014.05.034</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014006000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV012111546</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-5273(14)01017-1</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Coats, Andrew J. Stewart</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Protecting the pipeline of science: Openness, scientific methods and the lessons from ticagrelor and the PLATO trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ticagrelor, a potent antiplatelet, has been shown to be beneficial in patients with acute coronary syndromes in a randomised controlled trial published in a highly ranked peer reviewed journal. Accordingly it has entered guidelines and has been approved for clinical use by authorities. However, there remains a controversy regarding aspects of the PLATO trial, which are not immediately apparent from the peer-reviewed publications. A number of publications have sought to highlight potential discrepancies, using data available in publicly published documents from the US Food and Drug Administration (FDA) leading to disagreement regarding the value of open science and data sharing. We reflect upon potential sources of bias present in even rigorously performed randomised controlled trials, on whether peer review can establish the presence of bias and the need to constantly challenge and question even accepted data.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nijjer, Sukhjinder S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Francis, Darrel P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Fabersani, Emanuel ELSEVIER</subfield><subfield code="t">Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000849189</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:176</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:3</subfield><subfield code="g">day:20</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:600-604</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijcard.2014.05.034</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">176</subfield><subfield code="j">2014</subfield><subfield code="e">3</subfield><subfield code="b">20</subfield><subfield code="c">1020</subfield><subfield code="h">600-604</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4005365 |